PRTA PROTHENA CORP PUBLIC LTD CO
Pharmaceutical Preparations · Nasdaq · SEC CIK 1559053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY347.4%
TTM net income YoY91.5%
TTM EPS YoY91.3%
Revenue 3-yr CAGR-27.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-64.6%
Net margin-45.4%
FCF margin—
EBITDA margin-63.1%
Returns
ROE-8.5%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.17x
Leverage & solvency
Liabilities / assets5.2%
Debt / equity0.00x
Current ratio23.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.31x
Accruals ratio2.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $9.68M | $135.16M | $91.37M | $53.91M | $200.58M |
| R&D expense | $134.85M | $222.52M | $220.57M | $135.56M | $82.28M |
| SG&A expense | $59.39M | $67.20M | $61.84M | $49.90M | $46.32M |
| Operating income | -$214.64M | -$154.56M | -$191.04M | -$131.56M | $71.97M |
| Pretax income | -$200.83M | -$128.93M | -$160.48M | -$125.61M | $71.92M |
| Income tax | $43.26M | -$6.62M | -$13.45M | -$8.66M | $4.95M |
| Net income | -$244.09M | -$122.31M | -$147.03M | -$116.95M | $66.97M |
| EBITDA | -$213.75M | -$153.67M | -$190.11M | -$130.81M | $73.09M |
| EPS (basic) | -4.53 | -2.27 | -2.76 | -2.47 | 1.51 |
| EPS (diluted) | -4.53 | -2.27 | -2.76 | -2.47 | 1.38 |
| Weighted avg. shares (diluted) | 53.83M | 53.77M | 53.22M | 47.37M | 48.46M |
| Banking | |||||
| Net interest income | $14.14M | $25.82M | $31.01M | $6.35M | $42,000 |
| Balance sheet | |||||
| Cash & equivalents | $307.53M | $472.25M | $618.83M | $712.62M | $580.45M |
| Receivables | — | $0 | $5.16M | $0 | $0 |
| Current assets | $315.19M | $485.41M | $639.28M | $719.10M | $584.81M |
| PP&E, net | $2.14M | $3.08M | $3.84M | $1.73M | $2.01M |
| Total assets | $326.80M | $547.11M | $696.38M | $758.03M | $609.37M |
| Current liabilities | $40.84M | $48.50M | $56.89M | $50.15M | $33.45M |
| Total liabilities | $46.33M | $60.18M | $135.02M | $135.99M | $143.32M |
| Shareholders' equity | $280.47M | $486.93M | $561.37M | $622.04M | $466.04M |
| Shares outstanding | 53.83M | 53.83M | 53.68M | 52.10M | 46.66M |
| Cash flow statement | |||||
| Operating cash flow | -$163.58M | -$150.05M | -$133.91M | -$108.82M | $92.61M |
| Investing cash flow | -$138,000 | -$298,000 | -$2.77M | -$464,000 | -$575,000 |
| Financing cash flow | -$139,000 | $1.55M | $45.10M | $241.46M | $190.33M |
| Depreciation & amortization | $895,000 | $893,000 | $928,000 | $744,000 | $1.11M |
| Stock-based compensation | $37.64M | $45.96M | $40.91M | $31.32M | $24.66M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.